Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors
NCT05361954
·
clinicaltrials.gov ↗
PHASE1
Phase
NOT_YET_RECRUITING
Status
36
Enrollment
INDUSTRY
Sponsor class
Conditions
Cancer
Cancer of Pancreas
Sarcoma
Hepatic Metastasis
Solid Tumor
Interventions
DRUG:
STI-1386
Sponsor
Sorrento Therapeutics, Inc.